MetaCap

MaxCyte Cash Flow Statement

NASDAQ: MXCTHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD

1.37+0.09 (+7.03%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MaxCyte free cash flow

In fiscal 2025, MaxCyte generated -$34.4 million of operating cash flow and spent $1.8 million on capital expenditures. That left free cash flow of -$36.2 million, a free-cash-flow margin of -109.5% of revenue.

Summary generated from market data by MetaCap's automated system. Methodology

MaxCyte cash flow statement (annual)

MaxCyte annual cash flow statement
Fiscal year (USD)FY 20252025-12-31FY 20242024-12-31FY 20232023-12-31FY 20222022-12-31FY 20212021-12-31FY 20202020-12-31FY 20192019-12-31
Net Income-44.63M-41.05M-37.92M-23.57M-19.08M-11.82M-12.89M
Net Income growth (YoY)———————
Depreciation & Amortization4.34M4.32M4.17M2.70M1.42M1.05M613.50K
Stock-Based Compensation9.21M13.08M13.98M11.75M7.96M2.47M1.75M
Change in Working Capital954.00K6.16M8.09M-7.01M3.61M2.38M3.32M
Operating Cash Flow-34.41M-27.61M-21.69M-14.78M-10.68M-8.78M-8.80M
Capital Expenditures-1.77M-1.65M-3.70M-18.48M-3.83M-2.07M-1.27M
Investing Cash Flow25.93M6.93M54.98M-24.82M-195.01M-16.58M454.50K
Financing Cash Flow656.00K2.06M2.14M2.89M234.72M28.90M12.31M
Net Change in Cash-7.82M-18.62M35.44M-36.72M29.03M3.54M3.96M
Free Cash Flow-36.18M-29.26M-25.39M-33.26M-14.51M-10.85M-10.07M

This table shows 7 annual periods of MaxCyte's cash flow statement, from FY 2025 back to FY 2019, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow MXCT's reporting calendar. What is a cash flow statement?

More financial data